Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription


Articles published in Oncol Rep

Retrieve available abstracts of 75 articles:
HTML format
Text format



Single Articles


    November 2018
  1. MLYNSKA A, Salciuniene G, Zilionyte K, Garberyte S, et al
    Chemokine profiling in serum from patients with ovarian cancer reveals candidate biomarkers for recurrence and immune infiltration.
    Oncol Rep. 2018 Nov 27. doi: 10.3892/or.2018.6886.
    PubMed     Text format     Abstract available


  2. LU DH, Yang J, Gao LK, Min J, et al
    Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelialmesenchymal transition.
    Oncol Rep. 2018 Nov 27. doi: 10.3892/or.2018.6888.
    PubMed     Text format     Abstract available


  3. WANG X, Han L, Zhou L, Wang L, et al
    Prediction of candidate RNA signatures for recurrent ovarian cancer prognosis by the construction of an integrated competing endogenous RNA network.
    Oncol Rep. 2018;40:2659-2673.
    PubMed     Text format     Abstract available


    October 2018
  4. ALSAMMAN K, El-Masry OS
    Staurosporine alleviates cisplatin chemoresistance in human cancer cell models by suppressing the induction of SQSTM1/p62.
    Oncol Rep. 2018;40:2157-2162.
    PubMed     Text format     Abstract available


    September 2018
  5. GUO H, Xu Y, Wang F, Shen Z, et al
    Clinical associations between ASCT2 and pmTOR in the pathogenesis and prognosis of epithelial ovarian cancer.
    Oncol Rep. 2018 Sep 24. doi: 10.3892/or.2018.6729.
    PubMed     Text format     Abstract available


  6. WANG YJ, Zheng LY, Wang ZF, Song R, et al
    Associations of genewide SNPs in SNAI1 and TWIST1 with breast cancer and ovarian cancer susceptibility among Chinese Han women.
    Oncol Rep. 2018 Sep 21. doi: 10.3892/or.2018.6725.
    PubMed     Text format     Abstract available


    August 2018
  7. XIANG J, Zhou L, Zhuang Y, Zhang J, et al
    Lactate dehydrogenase is correlated with clinical stage and grade and is downregulated by siSTAB1 in ovarian cancer.
    Oncol Rep. 2018 Aug 17. doi: 10.3892/or.2018.6658.
    PubMed     Text format     Abstract available


  8. LU YM, Wang Y, Liu SQ, Zhou MY, et al
    Profile and validation of dysregulated long noncoding RNAs and mRNAs in ovarian cancer.
    Oncol Rep. 2018 Aug 17. doi: 10.3892/or.2018.6654.
    PubMed     Text format     Abstract available


    July 2018
  9. SHISHIDO A, Mori S, Yokoyama Y, Hamada Y, et al
    Mesothelial cells facilitate cancer stemlike properties in spheroids of ovarian cancer cells.
    Oncol Rep. 2018 Jul 27. doi: 10.3892/or.2018.6605.
    PubMed     Text format     Abstract available


  10. MORIKAWA A, Hayashi T, Kobayashi M, Kato Y, et al
    Somatic copy number alterations have prognostic impact in patients with ovarian clear cell carcinoma.
    Oncol Rep. 2018;40:309-318.
    PubMed     Text format     Abstract available


  11. KAWAI Y, Shibata K, Sakata J, Suzuki S, et al
    KIF20A expression as a prognostic indicator and its possible involvement in the proliferation of ovarian clearcell carcinoma cells.
    Oncol Rep. 2018;40:195-205.
    PubMed     Text format     Abstract available


    June 2018
  12. YANG T, Cheng J, You J, Yan B, et al
    S100B promotes chemoresistance in ovarian cancer stem cells by regulating p53.
    Oncol Rep. 2018 Jun 27. doi: 10.3892/or.2018.6527.
    PubMed     Text format     Abstract available


  13. WEI Y, Han T, Wang R, Wei J, et al
    [Corrigendum] LSD1 negatively regulates autophagy through the mTOR signaling pathway in ovarian cancer cells.
    Oncol Rep. 2018 Jun 14. doi: 10.3892/or.2018.6495.
    PubMed     Text format     Abstract available


  14. SANCHEZ-CARRANZA JN, Diaz JF, Redondo-Horcajo M, Barasoain I, et al
    Gallic acid sensitizes paclitaxel-resistant human ovarian carcinoma cells through an increase in reactive oxygen species and subsequent downregulation of ERK activation.
    Oncol Rep. 2018;39:3007-3014.
    PubMed     Text format     Abstract available


    May 2018
  15. WEI Y, Han T, Wang R, Wei J, et al
    LSD1 negatively regulates autophagy through the mTOR signaling pathway in ovarian cancer cells.
    Oncol Rep. 2018 May 10. doi: 10.3892/or.2018.6432.
    PubMed     Text format     Abstract available


  16. WANG L, Zhang F, Cui JY, Chen L, et al
    CAFs enhance paclitaxel resistance by inducing EMT through the IL6/JAK2/STAT3 pathway.
    Oncol Rep. 2018;39:2081-2090.
    PubMed     Text format     Abstract available


    April 2018
  17. LIN Q, Guan W, Ren W, Zhang L, et al
    MALAT1 affects ovarian cancer cell behavior and patient survival.
    Oncol Rep. 2018 Apr 19. doi: 10.3892/or.2018.6384.
    PubMed     Text format     Abstract available


  18. ZHAN SJ, Liu B, Linghu H
    Identifying genes as potential prognostic indicators in patients with serous ovarian cancer resistant to carboplatin using integrated bioinformatics analysis.
    Oncol Rep. 2018 Apr 19. doi: 10.3892/or.2018.6383.
    PubMed     Text format     Abstract available


  19. GARCIA-VAZQUEZ R, Gallardo Rincon D, Ruiz-Garcia E, Meneses Garcia A, et al
    let-7d-3p is associated with apoptosis and response to neoadjuvant chemotherapy in ovarian cancer.
    Oncol Rep. 2018 Apr 12. doi: 10.3892/or.2018.6366.
    PubMed     Text format     Abstract available


  20. CHEN Z, Zhu J, Zhu Y, Wang J, et al
    MicroRNA-616 promotes the progression of ovarian cancer by targeting TIMP2.
    Oncol Rep. 2018 Apr 12. doi: 10.3892/or.2018.6368.
    PubMed     Text format     Abstract available


    March 2018
  21. SONG K, Lv T, Chen Y, Diao Y, et al
    Emodin inhibits TGF-beta2 by activating the FOXD3/miR199a axis in ovarian cancer cells in vitro.
    Oncol Rep. 2018 Mar 6. doi: 10.3892/or.2018.6301.
    PubMed     Text format     Abstract available


  22. XU L, Xie Q, Qi L, Wang C, et al
    Bcl-2 overexpression reduces cisplatin cytotoxicity by decreasing ER-mitochondrial Ca2+ signaling in SKOV3 cells.
    Oncol Rep. 2018;39:985-992.
    PubMed     Text format     Abstract available


    February 2018
  23. CUI Y, Wu F, Tian D, Wang T, et al
    miR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8.
    Oncol Rep. 2018 Feb 12. doi: 10.3892/or.2018.6259.
    PubMed     Text format     Abstract available


  24. JANYST K, Janyst M, Siernicka M, Lasek W, et al
    Synergistic antitumor effects of histone deacetylase inhibitor scriptaid and bortezomib against ovarian cancer cells.
    Oncol Rep. 2018 Feb 6. doi: 10.3892/or.2018.6248.
    PubMed     Text format     Abstract available


  25. LIU L, Wang X, Li X, Wu X, et al
    Upregulation of IGF1 by tumor-associated macrophages promotes the proliferation and migration of epithelial ovarian cancer cells.
    Oncol Rep. 2018;39:818-826.
    PubMed     Text format     Abstract available


    January 2018
  26. ZHONG A, Zhang H, Xie S, Deng M, et al
    Inhibition of MUS81 improves the chemical sensitivity of olaparib by regulating MCM2 in epithelial ovarian cancer.
    Oncol Rep. 2018 Jan 22. doi: 10.3892/or.2018.6229.
    PubMed     Text format     Abstract available


  27. FUJIKAKE K, Kajiyama H, Yoshihara M, Nishino K, et al
    A novel mechanism of neovascularization in peritoneal dissemination via cancer-associated mesothelial cells affected by TGF-beta derived from ovarian cancer.
    Oncol Rep. 2018;39:193-200.
    PubMed     Text format     Abstract available


    December 2017
  28. HU H, Huang G, Wang H, Li X, et al
    Inhibition effect of triptolide on human epithelial ovarian cancer via adjusting cellular immunity and angiogenesis.
    Oncol Rep. 2017 Dec 15. doi: 10.3892/or.2017.6158.
    PubMed     Text format     Abstract available


  29. ZHANG N, Qiu J, Zheng T, Zhang X, et al
    Goserelin promotes the apoptosis of epithelial ovarian cancer cells by upregulating forkhead box O1 through the PI3K/AKT signaling pathway.
    Oncol Rep. 2017 Dec 15. doi: 10.3892/or.2017.6159.
    PubMed     Text format     Abstract available


  30. HAO Y, Zhu L, Yan L, Liu J, et al
    c-Fos mediates alpha1, 2-fucosyltransferase 1 and Lewis y expression in response to TGF-beta1 in ovarian cancer.
    Oncol Rep. 2017;38:3355-3366.
    PubMed     Text format     Abstract available


    October 2017
  31. XIE X, Yang M, Ding Y, Yu L, et al
    Formyl peptide receptor 2 expression predicts poor prognosis and promotes invasion and metastasis in epithelial ovarian cancer.
    Oncol Rep. 2017 Oct 13. doi: 10.3892/or.2017.6034.
    PubMed     Text format     Abstract available


    September 2017
  32. SU F, Geng J, Li X, Qiao C, et al
    SP1 promotes tumor angiogenesis and invasion by activating VEGF expression in an acquired trastuzumabresistant ovarian cancer model.
    Oncol Rep. 2017 Sep 25. doi: 10.3892/or.2017.5998.
    PubMed     Text format     Abstract available


  33. GAO J, Zhu H, Wan H, Zou X, et al
    Harmine suppresses the proliferation and migration of human ovarian cancer cells through inhibiting ERK/CREB pathway.
    Oncol Rep. 2017 Sep 13. doi: 10.3892/or.2017.5952.
    PubMed     Text format     Abstract available


  34. PARK GB, Kim D
    TLR5/7-mediated PI3K activation triggers epithelial-mesenchymal transition of ovarian cancer cells through WAVE3-dependent mesothelin or OCT4/SOX2 expression.
    Oncol Rep. 2017 Sep 6. doi: 10.3892/or.2017.5941.
    PubMed     Text format     Abstract available


    August 2017
  35. JIA L, Zhou J, Zhao H, Jin H, et al
    Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snailglycolysis pathways.
    Oncol Rep. 2017 Aug 7. doi: 10.3892/or.2017.5886.
    PubMed     Text format     Abstract available


    July 2017
  36. ZHANG J, Liu L, Han S, Li Y, et al
    B7-H3 is related to tumor progression in ovarian cancer.
    Oncol Rep. 2017 Jul 31. doi: 10.3892/or.2017.5858.
    PubMed     Text format     Abstract available


  37. BAE JS, Lee J, Park Y, Park K, et al
    Attenuation of MUC4 potentiates the anticancer activity of auranofin via regulation of the Her2/Akt/FOXO3 pathway in ovarian cancer cells.
    Oncol Rep. 2017 Jul 28. doi: 10.3892/or.2017.5853.
    PubMed     Text format     Abstract available


  38. GUO X, Guo N, Zhao J, Cai Y, et al
    Active targeting co-delivery system based on hollow mesoporous silica nanoparticles for antitumor therapy in ovarian cancer stem-like cells.
    Oncol Rep. 2017 Jul 18. doi: 10.3892/or.2017.5829.
    PubMed     Text format     Abstract available


  39. LIU N, Peng SM, Zhan GX, Yu J, et al
    Human chorionic gonadotropin beta regulates epithelial-mesenchymal transition and metastasis in human ovarian cancer.
    Oncol Rep. 2017 Jul 14. doi: 10.3892/or.2017.5818.
    PubMed     Text format     Abstract available


  40. FENG D, Zhao T, Yan K, Liang H, et al
    Gonadotropins promote human ovarian cancer cell migration and invasion via a cyclooxygenase 2-dependent pathway.
    Oncol Rep. 2017 Jul 3. doi: 10.3892/or.2017.5784.
    PubMed     Text format     Abstract available


  41. QIU S, Sun L, Jin Y, An Q, et al
    Silencing of BAG3 promotes the sensitivity of ovarian cancer cells to cisplatin via inhibition of autophagy.
    Oncol Rep. 2017;38:309-316.
    PubMed     Text format     Abstract available


    June 2017
  42. FU X, Xu L, Qi L, Tian H, et al
    BMH-21 inhibits viability and induces apoptosis by p53-dependent nucleolar stress responses in SKOV3 ovarian cancer cells.
    Oncol Rep. 2017 Jun 23. doi: 10.3892/or.2017.5750.
    PubMed     Text format     Abstract available


  43. CHEN X, Ying X, Wang X, Wu X, et al
    Exosomes derived from hypoxic epithelial ovarian cancer deliver microRNA-940 to induce macrophage M2 polarization.
    Oncol Rep. 2017 Jun 6. doi: 10.3892/or.2017.5697.
    PubMed     Text format     Abstract available


    May 2017
  44. CAO S, Chen C, Xue J, Huang Y, et al
    Silencing of type Igamma phosphatidylinositol phosphate kinase suppresses ovarian cancer cell proliferation, migration and invasion.
    Oncol Rep. 2017 May 25. doi: 10.3892/or.2017.5670.
    PubMed     Text format     Abstract available


  45. SHAO G, Lai W, Wan X, Xue J, et al
    Inactivation of EGFR/AKT signaling enhances TSA-induced ovarian cancer cell differentiation.
    Oncol Rep. 2017;37:2891-2896.
    PubMed     Text format     Abstract available


  46. WINKLER I, Pyszniak M, Pogoda K, Semczuk A, et al
    Assessment of Th17 lymphocytes and cytokine IL17A in epithelial ovarian tumors.
    Oncol Rep. 2017;37:3107-3115.
    PubMed     Text format     Abstract available


  47. CHO SY, Kim K, Park MS, Jang MY, et al
    Expression of Yes-associated protein 1 and its clinical significance in ovarian serous cystadenocarcinoma.
    Oncol Rep. 2017;37:2620-2632.
    PubMed     Text format     Abstract available


    April 2017
  48. NAKAMURA K, Terai Y, Tanabe A, Ono YJ, et al
    CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.
    Oncol Rep. 2017 Apr 19. doi: 10.3892/or.2017.5583.
    PubMed     Text format     Abstract available


  49. LIU Y, Li H, Ban Z, Nai M, et al
    Annexin A2 inhibition suppresses ovarian cancer progression via regulating beta-catenin/EMT.
    Oncol Rep. 2017 Apr 18. doi: 10.3892/or.2017.5578.
    PubMed     Text format     Abstract available


    March 2017
  50. GAO Y, Liu X, Li T, Wei L, et al
    Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer.
    Oncol Rep. 2017 Mar 27. doi: 10.3892/or.2017.5534.
    PubMed     Text format     Abstract available


  51. PARK GB, Chung YH, Kim D
    Induction of galectin-1 by TLR-dependent PI3K activation enhances epithelial-mesenchymal transition of metastatic ovarian cancer cells.
    Oncol Rep. 2017 Mar 27. doi: 10.3892/or.2017.5533.
    PubMed     Text format     Abstract available


  52. LIU XX, Ye H, Wang P, Li LX, et al
    Proteomic-based identification of HSP70 as a tumor-associated antigen in ovarian cancer.
    Oncol Rep. 2017 Mar 24. doi: 10.3892/or.2017.5525.
    PubMed     Text format     Abstract available


  53. ZHANG Q, Chen WM, Zhang XX, Zhang HX, et al
    Overexpression of salusin-beta is associated with poor prognosis in ovarian cancer.
    Oncol Rep. 2017;37:1826-1832.
    PubMed     Text format     Abstract available


  54. YAN H, Qiu L, Xie X, Yang H, et al
    ELF5 in epithelial ovarian carcinoma tissues and biological behavior in ovarian carcinoma cells.
    Oncol Rep. 2017;37:1412-1418.
    PubMed     Text format     Abstract available


  55. SATO M, Kawana K, Adachi K, Fujimoto A, et al
    Low uptake of fluorodeoxyglucose in positron emission tomography/computed tomography in ovarian clear cell carcinoma may reflect glutaminolysis of its cancer stem cell-like properties.
    Oncol Rep. 2017;37:1883-1888.
    PubMed     Text format     Abstract available


    January 2017
  56. GU G, Chen Y, Duan C, Zhou L, et al
    Overexpression of ARF1 is associated with cell proliferation and migration through PI3K signal pathway in ovarian cancer.
    Oncol Rep. 2017 Jan 18. doi: 10.3892/or.2017.5388.
    PubMed     Text format     Abstract available


  57. KIM BR, Kwon Y, Rho SB
    BMI-1 interacts with sMEK1 and inactivates sMEK1-induced apoptotic cell death.
    Oncol Rep. 2017;37:579-586.
    PubMed     Text format     Abstract available


    December 2016
  58. ZHANG H, Li W
    Dysregulation of micro-143-3p and BALBP1 contributes to the pathogenesis of the development of ovarian carcinoma.
    Oncol Rep. 2016;36:3605-3610.
    PubMed     Text format     Abstract available


    November 2016
  59. LONG Q, Yang R, Lu W, Zhu W, et al
    Adenovirus-mediated truncated Bid overexpression induced by the Cre/LoxP system promotes the cell apoptosis of CD133+ ovarian cancer stem cells.
    Oncol Rep. 2016 Nov 21. doi: 10.3892/or.2016.5263.
    PubMed     Text format     Abstract available


  60. SHEN Y, Zhang XY, Chen X, Fan LL, et al
    Synthetic paclitaxel-octreotide conjugate reverses the resistance of paclitaxel in A2780/Taxol ovarian cancer cell line.
    Oncol Rep. 2016 Nov 18. doi: 10.3892/or.2016.5260.
    PubMed     Text format     Abstract available


    October 2016
  61. YE J, Chen W, Wu ZY, Zhang JH, et al
    Upregulated CTHRC1 promotes human epithelial ovarian cancer invasion through activating EGFR signaling.
    Oncol Rep. 2016 Oct 24. doi: 10.3892/or.2016.5198.
    PubMed     Text format     Abstract available


  62. LI J, Huang H, Li Y, Li L, et al
    Decreased expression of long non-coding RNA GAS5 promotes cell proliferation, migration and invasion, and indicates a poor prognosis in ovarian cancer.
    Oncol Rep. 2016 Oct 24. doi: 10.3892/or.2016.5200.
    PubMed     Text format     Abstract available


  63. SANG XB, Sun KX, Wang LL, Chen S, et al
    Effects and mechanism of RhoC downregulation in suppressing ovarian cancer stem cell proliferation, drug resistance, invasion and metastasis.
    Oncol Rep. 2016 Oct 11. doi: 10.3892/or.2016.5164.
    PubMed     Text format     Abstract available


  64. GUO P, Xiong X, Zhang S, Peng D, et al
    miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin.
    Oncol Rep. 2016 Oct 3. doi: 10.3892/or.2016.5140.
    PubMed     Text format     Abstract available


    September 2016
  65. ZHU Q, Wu X, Wu Y, Wang X, et al
    Interaction between Treg cells and tumor-associated macrophages in the tumor microenvironment of epithelial ovarian cancer.
    Oncol Rep. 2016 Sep 28. doi: 10.3892/or.2016.5136.
    PubMed     Text format     Abstract available


  66. LU W, Lu T, Wei X
    Downregulation of DNMT3a expression increases miR-182-induced apoptosis of ovarian cancer through caspase-3 and caspase-9-mediated apoptosis and DNA damage response.
    Oncol Rep. 2016 Sep 28. doi: 10.3892/or.2016.5134.
    PubMed     Text format     Abstract available


  67. MENG Y, Hu J, Chen Y, Yu T, et al
    Silencing MARCH1 suppresses proliferation, migration and invasion of ovarian cancer SKOV3 cells via downregulation of NF-kappaB and Wnt/beta-catenin pathways.
    Oncol Rep. 2016 Sep 8. doi: 10.3892/or.2016.5076.
    PubMed     Text format     Abstract available


    June 2016
  68. MA K, Wang C, Geng Q, Fan Y, et al
    Recombinant adeno-associated virus-delivered anginex inhibits angiogenesis and growth of HUVECs by regulating the Akt, JNK and NF-kappaB signaling pathways.
    Oncol Rep. 2016;35:3505-13.
    PubMed     Text format     Abstract available


    April 2016
  69. DEVOR EJ, Schickling BM, Reyes HD, Warrier A, et al
    Cullin-5, a ubiquitin ligase scaffold protein, is significantly underexpressed in endometrial adenocarcinomas and is a target of miR-182.
    Oncol Rep. 2016;35:2461-5.
    PubMed     Text format     Abstract available


  70. ELSNEROVA K, Mohelnikova-Duchonova B, Cerovska E, Ehrlichova M, et al
    Gene expression of membrane transporters: Importance for prognosis and progression of ovarian carcinoma.
    Oncol Rep. 2016;35:2159-70.
    PubMed     Text format     Abstract available


    March 2016
  71. YANG M, Xie X, Ding Y
    SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.
    Oncol Rep. 2016;35:1796-806.
    PubMed     Text format     Abstract available


    February 2016
  72. WENG Z, Gao H, Hu J, Fan Y, et al
    Isoalantolactone induces autophagic cell death in SKOV(3) human ovarian carcinoma cells via upregulation of PEA-15.
    Oncol Rep. 2016;35:833-40.
    PubMed     Text format     Abstract available


  73. TAKEDA T, Banno K, Okawa R, Yanokura M, et al
    ARID1A gene mutation in ovarian and endometrial cancers (Review).
    Oncol Rep. 2016;35:607-13.
    PubMed     Text format     Abstract available


  74. ZOU Y, Deng W, Wang F, Yu XH, et al
    A novel somatic MAPK1 mutation in primary ovarian mixed germ cell tumors.
    Oncol Rep. 2016;35:725-30.
    PubMed     Text format     Abstract available


  75. KIM BR, Lee SH, Park MS, Seo SH, et al
    MARCKSL1 exhibits anti-angiogenic effects through suppression of VEGFR-2-dependent Akt/PDK-1/mTOR phosphorylation.
    Oncol Rep. 2016;35:1041-8.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: